Our advisors

 

Expert advisors

The EHE Rare Cancer Charity (UK) will be dealing with different aspects of EHE in its daily operations including, as one of its core objectives, the periodic assessment of grant applications from research establishments and individuals.  Our Trustees will be advised on research and medical matters while performing their roles by our Research and Medical Advisory Board (RMAB) comprising the personnel shown below. This team, experienced with EHE cancer and/or cancer research, provides the charity with world-class cancer research and oncology expertise. This is essential to ensure, where relevant, that the correct analysis and decisions are made. In the case of research funding it will help ensure that we get the maximum benefit from every pound of research funds we award. The charity is extremely grateful to all members of the RMAB for the ongoing support, guidance and knowledge that they provide.


Dr Brian Rubin, MD, PhD is Professor of Pathology, Vice-Chair of Research within the Pathology Institute, and Director of Soft Tissue Pathology at the Cleveland Clinic. He received his PhD in molecular biology and his MD from Cornell University Medical College. He did his residency in Anatomic Pathology at Brigham and Women’s Hospital and received fellowship training in soft tissue pathology, bone pathology, and cancer genetics. Dr. Rubin has dedicated his career to a better understanding of the diagnosis and classification of soft tissue neoplasms, especially sarcomas, where he is a prominent figure nationally and internationally. He is widely regarded as a thought leader in the field and is a founding member of the International Society of Bone and Soft Tissue Pathology.

 


Dr Robin Jones is a medical oncologist, specialising in the treatment of bone and soft tissue sarcomas, and is Head of the Sarcoma Unit at the Royal Marsden Hospital in London. He has experience in conducting Phase I, II and III trials, as well translational studies in sarcoma. He trained in medical oncology at the Royal Marsden Hospital and between 2010 and 2014 he was Head of the Sarcoma Program at the University of Washington / Fred Hutchinson Cancer Research Center in Seattle. His main research interest focuses on clinical trials of novel agents and immunotherapy in sarcoma.

 


Dr Robin Young MBChB, MRCP, MSc, PhD is a consultant medical oncologist at Weston Park Hospital, Sheffield. He graduated from the University of Edinburgh in 1999. He moved to Sheffield in 2006 to undertake specialist medical oncology training, including three years as a Yorkshire Cancer Research clinical research fellow at the University of Sheffield. He was appointed a consultant medical oncologist at Weston Park Hospital in 2015. His clinical and research interests involve sarcoma and lung cancer. He is the principal investigator for Sheffield on a number of national and international clinical trials. His research interests focus on the role of the tumour microenvironment including the potential of vascular targeted therapy.

 


Dr. Silvia Stacchiotti, MD is a medical oncologist at the Istituto Nazionale Tumori in Milan, Italy. She has one of the most active EHE practices in the world. At the American Society of Clinical Oncoloy (ASCO) in 2013, Dr. Stacchiotti presented her research titled, “Sirolimus in advanced hemangioendothelioma,” which was the first encouraging study showing a response in EHE patients to mTor inhibitors. She presented more data at the Connective Tissue Oncology Society in 2015 that showed even more promise and raised interest among sarcoma specialists. Dr. Stacchiotti consults EHE patients from around the world.

 


Dr Oliver Pearce BSc (Hons), PhD is Group Leader at the Barts Cancer Institute in London. Oliver's lab at Bart's is focused on the tumour microenvironment (TME), where they are particularly interested in understanding the composition and function of the tumour extracellular matrix in immunosuppression. There is also a personal connection for Oliver as his cousin was diagnosed with EHE in 2005. Oliver initially joined the charity as a Trustee, bringing cancer research expertise into the Board of Trustees, but subsequently agreed to also join the charity’s Research and Medical Advisory Board.